Abstract 416P
Background
Ovarian cancer (OC), the most malignant gynecological tumor, exhibits diverse therapeutic responses. Patient-derived in vitro models for drug screening offer an individualized approach to overcome interpatient heterogeneity. Bypassing the limitations of xenografts and organoids, 3D bioprinting (3DP) offers high-throughput, high fidelity, and a drug screening timeline of 8 days, which is of clinical significance. We hereby reported the establishment of patient-derived 3DP-OC models with personalized drug sensitivity results in 41 patients.
Methods
Tumor specimens of newly diagnosed OC patients were collected at Peking Union Medical College Hospital (PUMCH) from 2022-07 to 2023-07, with informed consent and PUMCH ethics committee approval. Tumors were digested into cell suspensions and mixed with GelMA to a final concentration of 1×107cell/mL. 3DP-OC was fabricated by an extrusion-based bioprinter, and treated with a panel of chemo- and targeted therapy drugs in dose gradients at DIV 5. Cell viability was measured by CellTiter-Glo® assay after 72 hours for dose-response curves and IC50.
Results
We have established 3DP-OC in 41 cases, including 34 high-grade serous ovarian cancer, 4 ovarian clear cell carcinoma, 1 ovarian sarcoma, 1 endometrioid carcinoma and 1 neuroendocrine tumor. The success rate was 100% with consistent viability during bioprinting and extended culture of up to 2 weeks. IHC and IF staining verified the comparable expression of OC markers and Ki-67 between 3DP-OC and tumor tissue. Interpatient heterogeneous response of drugs was observed in paclitaxel, carboplatin, cisplatin, doxorubicin, niraparib, olaparib, anlotinib and lenvatinib. Drug synergy of paclitaxel and carboplatin, first-line treatment of OC, were tested on 5 cases with disparate responses. One of which was clear cell carcinoma with frequent clinical resistance to platin-based therapy, urging a necessity of personalized therapy.
Conclusions
We established 3DP-OC on 41 cases with exceptional efficiency. 3DP-OC demonstrated diverse drug responses, underlining its potential for precision medicine. Our ongoing research aims to correlate 3DP-OC drug responses with clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-058), National High Level Hospital Clinical Research Funding (2022-PUMCH-045, 2022-PUMCH-B-034) and National Natural Science Foundation of China (32271470).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract